A novel de novo frameshift deletion in EHMT1 in a patient with Kleefstra Syndrome results in decreased H3K9 dimethylation

Patrick R. Blackburn, Monique Williams, Margot A. Cousin, Nicole J. Boczek, Geoffrey J. Beek, Gwen A. Lomberk, Raul A. Urrutia, Dusica Babovic-Vuksanovic, Eric W Klee

Research output: Contribution to journalArticle

Abstract

Background: Kleefstra Syndrome (KS) (MIM# 610253) is an autosomal dominant disorder caused by haploinsufficiency of euchromatic histone methyltransferase-1 (EHMT1, GLP). EHMT1 (MIM# 607001) encodes a histone methyltransferase that heterodimerizes with EHMT2 (also known as G9a, MIM# 604599), which together are responsible for mono- and dimethylation of H3 lysine 9 (H3K9me1 and -me2), resulting in transcriptional repression of target genes. Methods: This report describes an 18-year-old woman with intellectual disability, severely limited speech, hypotonia, microcephaly, and facial dysmorphisms, who was found to have a novel de novo single-base frameshift deletion in EHMT1. Results: Functional studies using patient fibroblasts showed decreased H3K9me2 compared to wild-type control cells, thus providing a rapid confirmatory test that complements molecular studies. Conclusion: Whole exome sequencing revealed a novel frameshift deletion in EHMT1 after a lengthy diagnostic odyssey in this patient. Functional testing using this patient's fibroblasts provides proof-of-concept for the analysis of variants of uncertain significance that are predicted to impact EHMT1 enzymatic activity.

Original languageEnglish (US)
Pages (from-to)141-146
Number of pages6
JournalMolecular Genetics and Genomic Medicine
Volume5
Issue number2
DOIs
StatePublished - Jan 1 2017

Fingerprint

Fibroblasts
Exome
Haploinsufficiency
Microcephaly
Muscle Hypotonia
Glucagon-Like Peptide 1
Intellectual Disability
Lysine
Genes
Kleefstra Syndrome
histone methyltransferase

Keywords

  • EHMT1
  • functional validation
  • GLP
  • Kleefstra Syndrome
  • p.Arg310Aspfs*4
  • whole exome sequencing

ASJC Scopus subject areas

  • Genetics
  • Genetics(clinical)
  • Molecular Biology

Cite this

A novel de novo frameshift deletion in EHMT1 in a patient with Kleefstra Syndrome results in decreased H3K9 dimethylation. / Blackburn, Patrick R.; Williams, Monique; Cousin, Margot A.; Boczek, Nicole J.; Beek, Geoffrey J.; Lomberk, Gwen A.; Urrutia, Raul A.; Babovic-Vuksanovic, Dusica; Klee, Eric W.

In: Molecular Genetics and Genomic Medicine, Vol. 5, No. 2, 01.01.2017, p. 141-146.

Research output: Contribution to journalArticle

Blackburn, Patrick R. ; Williams, Monique ; Cousin, Margot A. ; Boczek, Nicole J. ; Beek, Geoffrey J. ; Lomberk, Gwen A. ; Urrutia, Raul A. ; Babovic-Vuksanovic, Dusica ; Klee, Eric W. / A novel de novo frameshift deletion in EHMT1 in a patient with Kleefstra Syndrome results in decreased H3K9 dimethylation. In: Molecular Genetics and Genomic Medicine. 2017 ; Vol. 5, No. 2. pp. 141-146.
@article{47566697d9714b6d866b5c49fb55b5e2,
title = "A novel de novo frameshift deletion in EHMT1 in a patient with Kleefstra Syndrome results in decreased H3K9 dimethylation",
abstract = "Background: Kleefstra Syndrome (KS) (MIM# 610253) is an autosomal dominant disorder caused by haploinsufficiency of euchromatic histone methyltransferase-1 (EHMT1, GLP). EHMT1 (MIM# 607001) encodes a histone methyltransferase that heterodimerizes with EHMT2 (also known as G9a, MIM# 604599), which together are responsible for mono- and dimethylation of H3 lysine 9 (H3K9me1 and -me2), resulting in transcriptional repression of target genes. Methods: This report describes an 18-year-old woman with intellectual disability, severely limited speech, hypotonia, microcephaly, and facial dysmorphisms, who was found to have a novel de novo single-base frameshift deletion in EHMT1. Results: Functional studies using patient fibroblasts showed decreased H3K9me2 compared to wild-type control cells, thus providing a rapid confirmatory test that complements molecular studies. Conclusion: Whole exome sequencing revealed a novel frameshift deletion in EHMT1 after a lengthy diagnostic odyssey in this patient. Functional testing using this patient's fibroblasts provides proof-of-concept for the analysis of variants of uncertain significance that are predicted to impact EHMT1 enzymatic activity.",
keywords = "EHMT1, functional validation, GLP, Kleefstra Syndrome, p.Arg310Aspfs*4, whole exome sequencing",
author = "Blackburn, {Patrick R.} and Monique Williams and Cousin, {Margot A.} and Boczek, {Nicole J.} and Beek, {Geoffrey J.} and Lomberk, {Gwen A.} and Urrutia, {Raul A.} and Dusica Babovic-Vuksanovic and Klee, {Eric W}",
year = "2017",
month = "1",
day = "1",
doi = "10.1002/mgg3.268",
language = "English (US)",
volume = "5",
pages = "141--146",
journal = "Molecular genetics & genomic medicine",
issn = "2324-9269",
publisher = "John Wiley and Sons Inc.",
number = "2",

}

TY - JOUR

T1 - A novel de novo frameshift deletion in EHMT1 in a patient with Kleefstra Syndrome results in decreased H3K9 dimethylation

AU - Blackburn, Patrick R.

AU - Williams, Monique

AU - Cousin, Margot A.

AU - Boczek, Nicole J.

AU - Beek, Geoffrey J.

AU - Lomberk, Gwen A.

AU - Urrutia, Raul A.

AU - Babovic-Vuksanovic, Dusica

AU - Klee, Eric W

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Background: Kleefstra Syndrome (KS) (MIM# 610253) is an autosomal dominant disorder caused by haploinsufficiency of euchromatic histone methyltransferase-1 (EHMT1, GLP). EHMT1 (MIM# 607001) encodes a histone methyltransferase that heterodimerizes with EHMT2 (also known as G9a, MIM# 604599), which together are responsible for mono- and dimethylation of H3 lysine 9 (H3K9me1 and -me2), resulting in transcriptional repression of target genes. Methods: This report describes an 18-year-old woman with intellectual disability, severely limited speech, hypotonia, microcephaly, and facial dysmorphisms, who was found to have a novel de novo single-base frameshift deletion in EHMT1. Results: Functional studies using patient fibroblasts showed decreased H3K9me2 compared to wild-type control cells, thus providing a rapid confirmatory test that complements molecular studies. Conclusion: Whole exome sequencing revealed a novel frameshift deletion in EHMT1 after a lengthy diagnostic odyssey in this patient. Functional testing using this patient's fibroblasts provides proof-of-concept for the analysis of variants of uncertain significance that are predicted to impact EHMT1 enzymatic activity.

AB - Background: Kleefstra Syndrome (KS) (MIM# 610253) is an autosomal dominant disorder caused by haploinsufficiency of euchromatic histone methyltransferase-1 (EHMT1, GLP). EHMT1 (MIM# 607001) encodes a histone methyltransferase that heterodimerizes with EHMT2 (also known as G9a, MIM# 604599), which together are responsible for mono- and dimethylation of H3 lysine 9 (H3K9me1 and -me2), resulting in transcriptional repression of target genes. Methods: This report describes an 18-year-old woman with intellectual disability, severely limited speech, hypotonia, microcephaly, and facial dysmorphisms, who was found to have a novel de novo single-base frameshift deletion in EHMT1. Results: Functional studies using patient fibroblasts showed decreased H3K9me2 compared to wild-type control cells, thus providing a rapid confirmatory test that complements molecular studies. Conclusion: Whole exome sequencing revealed a novel frameshift deletion in EHMT1 after a lengthy diagnostic odyssey in this patient. Functional testing using this patient's fibroblasts provides proof-of-concept for the analysis of variants of uncertain significance that are predicted to impact EHMT1 enzymatic activity.

KW - EHMT1

KW - functional validation

KW - GLP

KW - Kleefstra Syndrome

KW - p.Arg310Aspfs4

KW - whole exome sequencing

UR - http://www.scopus.com/inward/record.url?scp=85041429164&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041429164&partnerID=8YFLogxK

U2 - 10.1002/mgg3.268

DO - 10.1002/mgg3.268

M3 - Article

AN - SCOPUS:85041429164

VL - 5

SP - 141

EP - 146

JO - Molecular genetics & genomic medicine

JF - Molecular genetics & genomic medicine

SN - 2324-9269

IS - 2

ER -